Cancer Cell Reprogramming Screening for Target Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for cancer therapy focus on identifying target genes for molecular-targeted drugs, which is time-consuming and inefficient, and there is a lack of techniques for screening therapeutic drugs using cancer cell reprogramming.
Innovation Solution
A method involving the expression of exogenous cell regulatory factors in cancer cells, either with or without a test substance, to assess changes in cancer cell behavior, such as reprogramming or differentiation, allowing for the identification of therapeutic drugs without prior knowledge of the target protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If comprehensive analyses such as microarray method are used to identify target candidate proteins, then many genes encoding target candidate proteins can be found, but identification of a true target gene requires excessive experimentation
Solution Approach 1:
The invention extracts the essential function of target gene identification by using reprogramming factors that can indicate cancer cell transformation status. Instead of testing each candidate protein individually, the method extracts the key signal (reprogramming factor expression) that reveals whether a test substance has therapeutic effect, thereby eliminating excessive experimentation.
Solution Approach 2:
The invention introduces reprogramming factors as intermediary indicators. These factors serve as mediators between the test substance and the cancer cell's true state, providing a rapid readout of therapeutic effect without requiring direct identification of target genes. The reprogramming factors act as biological sensors that translate complex cellular responses into measurable signals.
2Reliability
If molecular-targeted drugs targeting specific proteins are used for cancer treatment, then therapeutic effect can be achieved, but the screening process for identifying effective target proteins is time-consuming
Solution Approach 1:
The invention inverts the traditional screening approach. Instead of testing substances against known target proteins to see if they bind, the method introduces reprogramming factors and observes whether test substances can suppress their expression or activity. This reverse approach allows simultaneous screening of multiple substances without prior knowledge of their targets, dramatically reducing screening time while maintaining reliability.
Solution Approach 2:
The cancer cells themselves provide the screening information through their response to reprogramming factors. The cells' natural tendency to resist reprogramming when target proteins are active serves as an automatic indicator of drug effectiveness, eliminating the need for separate identification steps.
3Measurement precision
If reprogramming factors are introduced into cancer cells to assess reprogramming, then changes in cancer cell behavior can be detected, but the process requires comparison between contact and no-contact conditions with test substance
Solution Approach 1:
The invention performs preliminary action by pre-introducing reprogramming factors into cancer cells before adding test substances. This preparation establishes a baseline state and enables direct observation of drug effects on reprogramming, simplifying the overall process by eliminating the need for separate setup procedures for each test condition.
Data Source
AI summary
The invention aims to provide a method of screening for a therapeutic drug for cancer as a molecular-targeted drug targeting some protein from a number of candidate target proteins, without identifying the true target protein. In particular, the invention provides a method of screening for a therapeutic drug for cancer, including (i) a step of expressing an exogenous cell regulatory factor in a target cancer cell under contact or no contact with a test substance, (ii) a step of confirming change in the cancer cell, and (iii) a step of selecting the test substance as a therapeutic drug for cancer when the change of cancer cell increased under contact with the test substance as compared to no contact therewith.